|Last Price$12.25||Day Change (%)0.16%|
|Open Price$12.25||Day Change ($)0.02|
|Day Range12.25–12.25||52-Week Range12.12–12.56|
As of Thu 02/10/2016 | USD
Pfizer Commends The FDA Advisory Committee’s Vote To Approve Proposed Biosimilar Infliximab, The First Biosimilar Monoclonal Antibody Reviewed, For All Eligible Indications
Pfizer Beats Expectations, but Guidance Disappoints -- 2nd Update
Global Cardiovascular Partnering Deal Trends, Players and Financials 2010-2016 - Research and Markets
UPDATE: Pfizer beats profit expectations, but provides downbeat outlook
Global Medical Device Packaging Market 2016-2020 - Demand for High-Barrier Films Increasing in the U.S. - Research and Markets
Novartis Profit Dives 57% on Eye-Care Woes --2nd Update
Drug Delivery Market Analysis - Forecast (2015-2020) - Prominent Players are 3M, Abbott Laboratories, Thermo Fischer Scientific, Medtronics, Roche & Baxter - Research and Markets
United States Pharmaceutical Preparation Market 2015 - Analysis And Forecast to 2020 - Research and Markets
Despite the high 39% premium to Hospira's stock price, we believe the acquisition price is justified based on Pfizer's ability to unlock more value with its global reach.
Welcome to Hospira's First Quarter 2014 Conference Call. All lines have been placed on listen-only mode to prevent any background noise. Following the speakers' remarks, there will be a question-and-answer period.